PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Francisco Partners to exit Aesynt

Technology-focused private equity firm Francisco Partners is to sell Aesynt to Omnicell for USD275 million. Francisco Partners acquired Aesynt in October 2013.

“It has been a true pleasure to partner with the Aesynt management team to transform the business,” says Chris Adams, partner at Francisco Partners and chairman of the Aesynt board of directors. “Through significant investment in new products – particularly new enterprise medication management software – the team significantly revitalised the organisation and returned it to rapid growth.”

Aesynt enables health systems to reduce cost and improve patient safety through the integration, automation, and management of medication preparation and delivery system-wide with the industry’s most comprehensive medication management portfolio.

“Francisco Partners provided valuable strategic support, capital, and resources that allowed us to execute on a strategic vision that fueled new growth,” says Kraig McEwen, Aesynt CEO. “Today, healthcare organisations embrace Aesynt’s robust medication management tools, which will complement Omnicell’s product portfolio and international footprint.”

“Aesynt brings distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics,” says Randall Lipps, CEO of Omnicell. “We expect that as a combined entity we can accelerate innovation in the marketplace by leveraging the combined strengths of the Aesynt and Omnicell teams. Choice, innovation and value make this a great acquisition for Omnicell and our customers.”

Omnicell’s financial advisor in this transaction was Greenhill & Co. LLC and Sidley Austin LLP, Cooley LLP and Jones Day served as legal counsel. Francisco Partners was advised by Robert W Baird & Co and Kirkland & Ellis LLP.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured